HCV NS3/4A protein activates HIV-1 transcription from its long terminal repeat

Virus Research

Volumn 135, Issue 1, 2008, Pages 155-160

  Wu, Xiaoyun ^a   Ishaq, Musarat ^a   Hu, Jiajie ^a   Guo, Deyin ^a  

^a School of Pharmaceutical Sciences   (China)

Author keywords

AP 1; Co infection; HCV; HIV; HIV 1 LTR; NS3 4A

Indexed keywords

VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS TRANSCRIPTION; WESTERN BLOTTING;

CARRIER PROTEINS; CELL LINE; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; MUTATION; SERINE ENDOPEPTIDASES; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 44349083552     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2008.03.006     Document Type: Article

References (48)

1. Bartenschlager R., hlborn-Laake L., Mous J., and Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 67 (1993) 3835-3844
2. Benezra M., Chevallier N., Morrison D.J., MacLachlan T.K., El-Deiry W.S., and Licht J.D. BRCA1 augments transcription by the NF-κB transcription factor by binding to the Rel domain of the p65/RelA subunit. J. Biol. Chem. 278 (2003) 26333-26341/
3. Benhamou Y., Di M.V., Bochet M., Colombet G., Thibault V., Liou A., Katlama C., and Poynard T. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34 (2001) 283-287
4. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., and Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13681-13686
5. Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R., and Snydman D.R. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32 (2001) 492-497
6. Boisvert J., He X.S., Cheung R., Keeffe E.B., Wright T., and Greenberg H.B. Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. J. Infect. Dis. 184 (2001) 827-835
7. Bonacini M., Lin H.J., and Hollinger F.B. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J. Acquir. Immune Defic. Syndr. 26 (2001) 340-344
8. Brau N., Salvatore M., Rios-Bedoya C.F., Fernandez-Carbia A., Paronetto F., Rodriguez-Orengo J.F., and Rodriguez-Torres M. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J. Hepatol. 44 (2006) 47-55
9. Canonne-Hergaux F., Aunis D., and Schaeffer E. Interactions of the transcription factor AP-1 with the long terminal repeat of different human immunodeficiency virus type 1 strains in Jurkat, glial, and neuronal cells. J. Virol. 69 (1995) 6634-6642
10. Caussin-Schwemling C., Schmitt C., and Stoll-Keller F. Study of infection of human blood derived monocyte/macrophages with hepatitis C virus in vitro. J. Med. Virol. 65 (2001) 14-22
11. Daar E.S., Lynn H., Donfield S., Gomperts E., Hilgartner M.W., Hoots W.K., Chernoff D., Arkin S., Wong W.Y., and Winkler C.A. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J. Acquir. Immune Defic. Syndr. 26 (2001) 466-472
12. El Kharroubi A., and Verdin E. Protein-DNA interactions within DNase I-hypersensitive sites located downstream of the HIV-1 promoter. J. Biol. Chem. 269 (1994) 19916-19924
13. Fuster D., Planas R., Muga R., Ballesteros A.L., Santos J., Tor J., Sirera G., Guardiola H., Salas A., Cabre E., Ojanguren I., Barluenga E., Rey-Joly C., Clotet B., and Tural C. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res. Hum. Retroviruses 20 (2004) 1293-1297
14. Gaynor R. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS 6 (1992) 347-363
15. Gosert R., Egger D., Lohmann V., Blum H.E., Bienz K., and Moradpour D. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J. Virol. 77 (2003) 5487-5492
16. Greub G., Ledergerber B., Battegay M., Grob P., Perrin L., Furrer H., Burgisser P., Erb P., Boggian K., Piffaretti J.C., Hirschel B., Janin P., Francioli P., Flepp M., and Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356 (2000) 1800-1805
17. Hassan M., Ghozlan H., and Bdel-Kader O. Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology 333 (2005) 324-336
18. Karin M., Liu Z., and Zandi E. AP-1 function and regulation. Curr. Opin. Cell Biol. 9 (1997) 240-246
19. Klenerman P., and Kim A. HCV-HIV coinfection: simple messages from a complex disease. PLoS. Med. 4 (2007) e240
20. Kumar A., Manna S.K., Dhawan S., and Aggarwal B.B. HIV-Tat protein activates c-Jun N-terminal kinase and activator protein-1. J. Immunol. 161 (1998) 776-781
21. Li Z., Xiong Y., Peng Y., Pan J., Chen Y., Wu X., Hussain S., Tien P., and Guo D. Specific inhibition of HIV-1 replication by short hairpin RNAs targeting human cyclin T1 without inducing apoptosis. FEBS Lett. 579 (2005) 3100-3106
22. Lin C., Pragai B.M., Grakoui A., Xu J., and Rice C.M. Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics. J. Virol. 68 (1994) 8147-8157
23. Lohmann V., Korner F., Koch J.-O., Herian U., Theilmann L., and Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
24. Macias J., Castellano V., Merchante N., Palacios R.B., Mira J.A., Saez C., Garcia-Garcia J.A., Lozano F., Gomez-Mateos J.M., and Pineda J.A. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 18 (2004) 767-774
25. Mallardo M., Dragonetti E., Baldassarre F., Ambrosino C., Scala G., and Quinto I. An NF-kappaB site in the 5′-untranslated leader region of the human immunodeficiency virus type 1 enhances the viral expression in response to NF-kappaB-activating stimuli. J. Biol. Chem. 271 (1996) 20820-20827
26. Messick K., Sanders J.C., Goedert J.J., and Eyster M.E. Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders. Haemophilia 7 (2001) 568-574
27. Montano M.A., Kripke K., Norina C.D., Achacoso P., Herzenberg L.A., Roy A.L., and Nolan G.P. NF-kappa B homodimer binding within the HIV-1 initiator region and interactions with TFII-I. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 12376-12381
28. Nabel G., and Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326 (1987) 711-713
29. Penin F., Dubuisson J., Rey F.A., Moradpour D., and Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 39 (2004) 5-19
30. Pereira L.A., Bentley K., Peeters A., Churchill M.J., and Deacon N.J. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res. 28 (2000) 663-668
31. Phares W., Franza Jr. B.R., and Herr W. The kappa B enhancer motifs in human immunodeficiency virus type 1 and simian virus 40 recognize different binding activities in human Jurkat and H9 T cells: evidence for NF-kappa B-independent activation of the kappa B motif. J. Virol. 66 (1992) 7490-7498
32. Rockstroh J.K., Mocroft A., Soriano V., Tural C., Losso M.H., Horban A., Kirk O., Phillips A., Ledergerber B., and Lundgren J. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J. Infect. Dis. 192 (2005) 992-1002
33. Rohr O., Marban C., Aunis D., and Schaeffer E. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J. Leukoc. Biol. 74 (2003) 736-749
34. Roulston A., Lin R., Beauparlant P., Wainberg M.A., and Hiscott J. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol. Rev. 59 (1995) 481-505
35. Salahuddin S.Z., Snyder K.A., Godwin A., Grewall R., Prichard J.G., Kelley A.S., and Revie D. The simultaneous presence and expression of human hepatitis C virus (HCV), human herpesvirus-6 (HHV-6), and human immunodeficiency virus-1 (HIV-1) in a single human T-cell. Virol J. 4 (2007) 106
36. Sawaya B.E., Rohr O., Aunis D., and Schaeffer E. Regulation of human immunodeficiency virus type 1 gene transcription by nuclear receptors in human brain cells. J. Biol. Chem. 271 (1996) 22895-22900
37. Schiavini M., Angeli E., Mainini A., Zerbi P., Duca P.G., Gubertini G., Vago L., Fociani P., Giorgi R., and Cargnel A. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med. 7 (2006) 331-337
38. Seo M.Y., Abrignani S., Houghton M., and Han J.H. Small interfering RNA-mediated inhibition of Hepatitis C virus replication in the human hepatoma cell line Huh-7. J. Virol. 77 (2003) 810-812
39. Sulkowski M.S., and Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J. Viral Hepat. 14 (2007) 371-386
40. Sulkowski M.S., Moore R.D., Mehta S.H., Chaisson R.E., and Thomas D.L. Hepatitis C and progression of HIV disease. JAMA 288 (2002) 199-206
41. Sung V.M., Shimodaira S., Doughty A.L., Picchio G.R., Can H., Yen T.S., Lindsay K.L., Levine A.M., and Lai M.M. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J. Virol. 77 (2003) 2134-2146
42. Tai C.L., Chi W.K., Chen D.S., and Hwang L.H. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J. Virol. 70 (1996) 8477-8484
43. Tian Y., Zhang Y., Zhong B., Wang Y.Y., Diao F.C., Wang R.P., Zhang M., Chen D.Y., Zhai Z.H., and Shu H.B. RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-triggered NF-kappaB activation by targeting TAB2/3 for degradation. J. Biol. Chem. 282 (2007) 16776-16782
44. Thomas D.L., Astemborski J., Vlahov D., Strathdee S.A., Ray S.C., Nelson K.E., Galai N., Nolt K.R., Laeyendecker O., and Todd J.A. Determinants of the quantity of hepatitis C virus RNA. J. Infect. Dis. 181 (2000) 844-851
45. Van Lint C., Amella C.A., Emiliani S., John M., Jie T., and Verdin E. Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J. Virol. 71 (1997) 6113-6127
46. Varin A., Manna S.K., Quivy V., Decrion A.Z., Van L.C., Herbein G., and Aggarwal B.B. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J. Biol. Chem. 278 (2003) 2219-2227
47. Xu L.G., Li L.Y., and Shu H.B. TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J. Biol. Chem. 279 (2004) 17278-17282
48. Yoo T.W., Donfield S., Lail A., Lynn H.S., and Daar E.S. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J. Infect. Dis. 191 (2005) 4-10